Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600735 | 0.81 | NQO2 (0.41) | LMNAMEN1CYP1A2CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL10586111 | 0.79 | NQO2 (0.40) | LMNAMEN1CYP1A2CYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL9803384 | 0.78 | NQO2 (0.39) | LMNAMEN1CYP1A2CYP3A4TSHR | |
| SCHEMBL3316223 | 0.77 | ALDH1A1 (0.54) | LMNAMEN1CYP3A4TSHRKMT2A | |
| Hydrochloric Acid SCHEMBL9859387 | 0.77 | NQO2 (0.38) | LMNAMEN1CYP1A2CYP3A4TSHR | |
| SCHEMBL14556505 | 0.75 | ALDH1A1 (0.39) | LMNAMEN1CYP1A2CYP3A4TSHR | |
| SCHEMBL11199104 | 0.75 | SLC16A3 (0.47) | MEN1CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL8497623 | 0.74 | CA1 (0.56) | MEN1CYP1A2CYP3A4CYP2C19KMT2A | |
| SCHEMBL10837346 | 0.73 | ALDH1A1 (0.50) | LMNAMEN1KMT2AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8498491 | 0.73 | CA1 (0.54) | MEN1CYP1A2CYP3A4CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | LMNA 1862/4885MEN1 921/4885CYP1A2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.